In this issue:
How useful are the modified New York criteria in early SpA?
Chondroitin/glucosamine sulphate: no benefit in knee OA
Lesinurad + allopurinol lowers serum uric acid in gout
Switching from infliximab reference product to its biosimilar in AS
. . . and RA shows no loss of efficacy and is safe
Tocilizumab 8 mg/kg: best option after anti-TNF failure in RA?
Abatacept in seronegative undifferentiated arthritis
Belimumab improves morbidity associated with SLE
Psoriatic arthritis increases risk of CV disease
Please login below to download this issue (PDF)